z-logo
open-access-imgOpen Access
Ncb2 Is Involved in Activated Transcription of CDR1 in Azole-Resistant Clinical Isolates of Candida albicans
Author(s) -
Shipra Shukla,
Vipin Yadav,
Gauranga Mukhopadhyay,
Rajendra Prasad
Publication year - 2011
Publication title -
eukaryotic cell
Language(s) - English
Resource type - Journals
eISSN - 1535-9778
pISSN - 1535-9786
DOI - 10.1128/ec.05041-11
Subject(s) - promoter , biology , chromatin immunoprecipitation , psychological repression , transcriptional regulation , transcription (linguistics) , gene , candida albicans , transcription factor , mutant , microbiology and biotechnology , gene expression , genetics , linguistics , philosophy
We recently demonstrated thatCDR1 overexpression in azole-resistant isolates ofCandida albicans is due to its enhanced transcriptional activation and increased mRNA stability. In this study, we provide the first evidence of transcriptional regulation ofCDR1 by Ncb2, the β subunit of NC2, a heterodimeric regulator of transcription. ConditionalNCB2 null mutants displayed decreased susceptibility toward azole and an enhanced transcription ofCDR1 . Interestingly, Ncb2 associated with theCDR1 promoter under both repression and activation; however, an increase in recruitment was observed under both transient and constitutive activation states. By chromatin immunoprecipitation (ChIP) assay, we showed the preferential recruitment of Ncb2 to the core TATA region under activation (azole-resistant isolate), while under repression (azole-susceptible isolate) it was present at the TATA upstream region. Further, ChIP analysis revealed that Ncb2 binding was not restricted to theCDR1 gene; instead, it was observed on the promoters of genes coregulated withCDR1 by the transcription activator Tac1. Thetac1 Δ null mutants, which fail to show the drug-induced transient activation ofCDR1 , also showed no increase in Ncb2 recruitment at the promoter. Taken together, our results show that Ncb2, in conjunction with Tac1, is involved in the transcriptional activation ofCDR1 , opening up new therapeutic possibilities to combat multidrug resistance (MDR) inC. albicans .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom